Autres langues Cyxone AB

Actions

Temps Différé Nasdaq Stockholm Autres places de cotation 14:49:02 17/05/2024			Varia. 5j.	Varia. 1 janv.
0,1385 ^SEK	+14,46%		+26,48%	+37,95%

22/04	Cyxone AB (publ) annonce des changements au niveau du directeur général	CI
25/03	Cyxone conclut un accord de recherche pour un traitement de la polyarthrite rhumatoïde	MT

Sweden's Cyxone Appoints New CEO	22/04
Kjell Stenberg new CEO in Cyxone AB	22/04
Cyxone AB Announces Chief Executive Officer Changes	22/04
BioStock: Cyxone comments on the clinical collaboration in the UK	28/03
Cyxone Enters Research Deal for Rheumatoid Arthritis Therapy	25/03
Cyxone enters important research collaboration	25/03
Cyxone Enters Important Research Collaboration with University of Glasgow	25/03
BioStock: Cyxone's CEO gives a status update	05/03
Cyxone AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02
BioStock: Cyxone identifies target protein for rabeximod	17/01
Cyxone reaches important milestone regarding mechanism of action	15/01
Cyxone Reaches an Important Milestone for the Drug Candidate Rabeximod	15/01
Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor	20/11
Interim Report 1 January to 30 September 2023	27/10/23
Cyxone AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/10/23
Cyxone to Receive Unitary Patent in EU for T20K Drug Candidate	09/10/23
Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K	09/10/23
BioStock Investor Meeting: Cyxone	27/09/23
Interim Report 1 January to 30 June 2023	30/08/23
Cyxone AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23

Aucun résultat pour cette recherche